Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
| 대상 질환 | Active Systemic Lupus Erythematosus |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | AstraZeneca |
| 상태 | 완료 |
| 참여자 수 | 277 명 |
| 중재(약물) | Anifrolumab |
| 시작일 | 2021년 9월 13일 |
| 완료일 | 2025년 4월 7일 |
| 결과 공개일 | 2026년 5월 20일 |
요약
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo
| Anifrolumab 300mg | 84 Participants |
|---|---|
| Placebo | 46 Participants |
| p-value | >0.999 |
|---|---|
| Rate difference (%) | 28.4 |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health